araag2/HINT huggingface dataset:
Clinical trial NCT02942017 (phase 3, status: completed)
Conditions: postpartum depression
ICD codes: F53.0
Drugs: placebo, sage-547 90 μg/kg/h
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)C(C)=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Participant either must have ceased lactating at screening; or if still lactating or
             actively breastfeeding at screening, agreed to temporarily cease giving breastmilk to
             their infant(s).

          -  Participant had a major depressive episode that began no earlier than the third
             trimester and no later than the first 4 weeks following delivery, as diagnosed by
             Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I).

          -  Participant had a HAM-D total score of ≥20 and ≤25 at screening and Day 1 (prior to
             dosing).

          -  Participant was ≤ six months postpartum.

          -  Participant was amenable to intravenous therapy.

        Key Exclusion Criteria:

          -  Active psychosis.

          -  Attempted suicide associated with index case of postpartum depression.

          -  Medical history of bipolar disorder.

        Note: Other protocol-defined inclusion/exclusion criteria applied.
Clinical trial NCT02942576 (phase 3, status: completed)
Conditions: atrial fibrillation
ICD codes: I48.0, I48.21, I48.91, I48.11, I48.19, I48.20
Drugs: edoxaban, vka-based regimen, vka-based regimen, vka-based regimen, vka-based regimen
SMILES: CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[C@@H](C1)NC(=O)C1=NC2=C(CN(C)CC2)S1, FC1=CC=C(C=C1)C1C(=O)C2=CC=CC=C2C1=O, FC1=CC=C(C=C1)C1C(=O)C2=CC=CC=C2C1=O, FC1=CC=C(C=C1)C1C(=O)C2=CC=CC=C2C1=O, FC1=CC=C(C=C1)C1C(=O)C2=CC=CC=C2C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female at least 18 years of age with documented history of paroxysmal (lasting
             ≤7 days), persistent (lasting >7 days but ≤12 months) or long-standing [long-lasting]
             persistent (>12 months) non-valvular AF. Duration of AF can be confirmed by any
             electrical tracing or a recording in the subject's medical records (e.g., medical
             chart, hospital discharge summary).

          -  Subject is eligible and is scheduled for either radio frequency (RF) or cryoballoon
             catheter ablation (both first and repeated procedure included).

          -  Signed informed consent form (ICF).

        Exclusion Criteria:

          -  AF considered to be of a transient or reversible nature (such as in myocarditis,
             post-surgery, ionic disturbances, thyrotoxicosis, pneumonia, severe anemia etc.).

          -  Subject post stroke, or with a systemic thromboembolic event within the past 6 months
             prior to randomization.

          -  Subject has a thrombus in the left atrial appendage (LAA), left atrium (LA), left
             ventricle (LV), or aorta, or an intracardial mass.

          -  Subject had a myocardial infarction (MI) within the 2 months prior to randomization or
             coronary artery bypass graft (CABG) surgery within 3 months prior to the
             randomization.

          -  Subject has signs of bleeding, history of clinically-relevant bleeding according to
             International Society on Thrombosis and Hemostasis (ISTH), or conditions associated
             with high risk of bleeding

          -  Subjects with any contraindication for anticoagulant agents.
Clinical trial NCT02943564 (phase 3, status: completed)
Conditions: depressive disorder, major
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: rapastinel, placebo
SMILES: C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(N)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)
             criteria for MDD

          -  Current major depressive episode of at least 8 weeks and not exceeding 18 months in
             duration at Visit 1

          -  Have no more than partial response (< 50% improvement) to ongoing treatment with a
             protocol-allowed antidepressant

          -  If female of childbearing potential, have a negative serum β-human chorionic
             gonadotropin (β-hCG) pregnancy test.

        Exclusion Criteria:

          -  DSM-5-based diagnosis of any disorder other than MDD that was the primary focus of
             treatment within 6 months before Visit 1

          -  Lifetime history of meeting DSM-5 criteria for:

               1. Schizophrenia spectrum or other psychotic disorder

               2. Bipolar or related disorder

               3. Major neurocognitive disorder

               4. Neurodevelopmental disorder of greater than mild severity or of a severity that
                  impacts the participant's ability to consent, follow study directions, or
                  otherwise safely participate in the study

               5. Dissociative disorder

               6. Posttraumatic stress disorder

               7. MDD with psychotic features

          -  Significant suicide risk, as judged by the Investigator.
Clinical trial NCT02943577 (phase 3, status: completed)
Conditions: depressive disorder, major
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: rapastinel, placebo
SMILES: C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(N)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)
             criteria for MDD

          -  Current major depressive episode of at least 8 weeks and not exceeding 18 months in
             duration at Visit 1

          -  Have no more than partial response (< 50% improvement) to ongoing treatment with a
             protocol-allowed antidepressant

          -  If female of childbearing potential, have a negative serum β-human chorionic
             gonadotropin (β-hCG) pregnancy test.

        Exclusion Criteria:

          -  DSM-5-based diagnosis of any disorder other than MDD that was the primary focus of
             treatment within 6 months before Visit 1

          -  Lifetime history of meeting DSM-5 criteria for:

               1. Schizophrenia spectrum or other psychotic disorder

               2. Bipolar or related disorder

               3. Major neurocognitive disorder

               4. Neurodevelopmental disorder of greater than mild severity or of a severity that
                  impacts the participant's ability to consent, follow study directions, or
                  otherwise safely participate in the study

               5. Dissociative disorder

               6. Posttraumatic stress disorder

               7. MDD with psychotic features

          -  Significant suicide risk, as judged by the Investigator.
Clinical trial NCT02953340 (phase 3, status: completed)
Conditions: neutropenia, breast cancer
ICD codes: D70.4, D70.8, D70.9, P61.5, D70.3, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: spi-2012, pegfilgrastim, docetaxel, cyclophosphamide
SMILES: CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Key Inclusion Criteria:

          -  New diagnosis of histologically confirmed early-stage breast cancer (ESBC), defined as
             operable Stage I to Stage IIIA breast cancer.

          -  Candidate to receive adjuvant or neo-adjuvant TC chemotherapy.

          -  ECOG ≤2.

          -  ANC ≥1.5×10^9/L.

          -  Platelet count ≥100×10^9/L.

          -  Hemoglobin >9 g/dL.

          -  Calculated creatinine clearance > 50 mL/min.

          -  Total bilirubin ≤1.5 mg/dL.

          -  AST/SGOT and ALT/SGPT ≤2.5×ULN. (upper limit of normal)

          -  Alkaline phosphatase ≤2.0×ULN.

        Key Exclusion Criteria:

          -  Active concurrent malignancy (except non melanoma skin cancer or carcinoma in situ of
             the cervix) or life-threatening disease.

          -  Known sensitivity to E. coli derived products.

          -  Concurrent adjuvant cancer therapy.

          -  Locally recurrent/metastatic.

          -  Previous exposure to filgrastim, pegfilgrastim, or other G-CSF products in clinical
             development within 12 months prior to the administration of study drug.

          -  Active infection or any serious underlying medical condition, which would impair the
             ability of the patient to receive protocol treatment.

          -  Prior bone marrow or stem cell transplant.

          -  Used any investigational drugs, biologics, or devices within 30 days prior to study
             treatment or plans to use any of these during the course of the study.

          -  Prior radiation therapy within 30 days prior to enrollment.

          -  Major surgery within 30 days prior to enrollment.
Clinical trial NCT02963935 (phase 3, status: completed)
Conditions: metabolism and nutrition disorder, obesity
ICD codes: E70.5, E71.32, E72.4, E76.9, E78.89, E83.2, E88.40, E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211
Drugs: liraglutide, placebo
SMILES: CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Informed consent obtained before any trial-related activities. Trial-related
             activities are any procedures that are carried out as part of the trial, including
             activities to determine suitability for the trial

          -  BMI above or equal to 30 kg/m^2

          -  Male or female, age 18 years or older at the time of signing informed consent

        Exclusion Criteria:

          -  HbA1c (glycosylated haemoglobin) above or equal to 6.5% (at screening visit), or
             diagnosis of type 1 or type 2 diabetes mellitus

          -  Recent history of cardiovascular disease (myocardial infarction or stroke within the
             past 6 months), severe congestive heart failure (NYHA class III, IV), or second degree
             or greater heart block

          -  Personal or family history of Medullary Thyroid Carcinoma (MTC), or Multiple Endocrine
             Neoplasia type 2 (MEN2)

          -  Female who is pregnant, breast-feeding or intends to become pregnant or is of
             child-bearing potential and not using an adequate contraceptive method (adequate
             contraceptive measure as required by local regulation or practice)

          -  Use in past 90 days of medications known to induce significant weight loss (e.g.,
             prescription weight loss medications) or weight gain (e.g., chronic use of oral
             steroids, second generation antipsychotics)

          -  History of pancreatitis (acute or chronic)

          -  History of major depressive disorder within the past 2 years

          -  Any lifetime history of a suicide attempt

          -  Inadequately treated blood pressure defined as Grade 3 hypertension or higher
             (Systolic above or equal to 180 mmHg or diastolic above or equal to 110 mmHg)

          -  History of malignancy (except for non-melanoma skin cancer) within the past 5 years
Clinical trial NCT02964247 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: liraglutide, placebo
SMILES: CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Informed consent obtained before any trial-related activities. Trial-related
             activities are any procedures that are carried out as part of the trial, including
             activities to determine suitability for the trial.

          -  Male or female, age 18 years or older at the time of signing informed consent.

          -  Diagnosed with type 2 diabetes mellitus.

          -  HbA1c of 7.0-9.5% (53-80 mmol/mol) (both inclusive).

          -  Stable dose of an SGLT-2 inhibitor as monotherapy or in combination (including
             fixed-dose drug combination) with a stable dose of metformin (1500 mg or more, or
             maximum tolerated dose) for at least 90 days prior to the day of screening. All
             medications in compliance with current local label.

          -  Body mass index of 20 kg/m^2 or above.

        Exclusion Criteria:

          -  Female who is pregnant, breast-feeding or intends to become pregnant or is of
             child-bearing potential and not using an adequate contraceptive method (adequate
             contraceptive measure as required by local regulation or practice).

          -  History of diabetic ketoacidosis while being treated with SGLT2 inhibitors.

          -  Renal impairment measured as estimated Glomerular Filtration Rate (eGFR) value of less
             than 60 mL/min/1.73m^2 as defined by Kidney Disease Improving Global Outcomes (KDIGO)
             classification using isotope dilution mass spectrometry (IDMS) for serum creatinine
             measured at screening.

          -  Treatment with any medication for the indication of diabetes or obesity other than
             stated in the inclusion criteria within the past 90 days prior to the day of
             screening. However, short term insulin treatment for a maximum of 14 days during the
             90 days prior to screening is allowed.

          -  Family or personal history of multiple endocrine neoplasia type 2 or medullary thyroid
             carcinoma. Family is defined as a first degree relative.

          -  History or presence of pancreatitis (acute or chronic).

          -  Impaired liver function, defined as ALT 2.5 or more times upper normal limit at
             screening.

          -  Subjects presently classified as being in New York Heart Association (NYHA) Class IV.
Clinical trial NCT02970292 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: pimavanserin, placebo
SMILES: CC(C)COC1=CC=C(CNC(=O)N(CC2=CC=C(F)C=C2)C2CCN(C)CC2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Adults patients, between 18 and 55 years of age

          2. A clinical diagnosis of schizophrenia with a minimum duration of 1 year

          3. The main background antipsychotic with which the subject is being treated must be one
             of the antipsychotics listed below:

               -  Aripiprazole

               -  Aripiprazole long-acting injectables:

                    -  Abilify Maintena®

                    -  Aristada®

               -  Risperidone

               -  Risperidone long-acting injection

               -  Olanzapine

               -  Lurasidone

               -  Cariprazine

               -  Brexpiprazole

               -  Asenapine

          4. Has had a partial but inadequate response to antipsychotic treatment

          5. Has a history of response to antipsychotic treatment other than clozapine

        Exclusion Criteria:

          1. Patient has a psychiatric disorder other than schizophrenia

          2. Patient has a history of resistance to antipsychotic treatment

          3. A urine drug screen (UDS) result at Baseline that indicates the presence of any tested
             prohibited substance of potential abuse, except marijuana

             a. Patients with a result indicating the presence of marijuana are permitted if they
             agree to abstain from marijuana use during the study and the medical monitor approves
             the subject's participation

          4. Patient has current evidence of a serious and/or unstable psychiatric, neurologic,
             cardiovascular, respiratory, gastrointestinal, renal, hepatic, hematologic, or other
             medical disorder, including cancer or malignancies, which would affect the patient's
             ability to participate in the program

          5. Patient has had a myocardial infarction in the last six months

          6. Patient is taking a medication or drug that prolongs the QT interval or has a family
             or personal history or symptoms of long QT syndrome

        Patients will be evaluated at screening to ensure that all criteria for study participation
        are met. Patients may be excluded from the study based on these assessments (and
        specifically if it is determined that their baseline health and psychiatric condition do
        not meet all pre-specified entry criteria).
Clinical trial NCT02973737 (phase 3, status: unknown status)
Conditions: her2 positive metastatic breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: pyrotinib, placebo, capecitabine
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          1. Aged ≥18 and ≤75 years.

          2. ECOG performance status of 0 to 1.

          3. Life expectancy of more than 12 weeks.

          4. According to RECIST 1.1, at least one measurable lesion exists

          5. Histologically or cytologic confirmed HER2 positive advanced breast cancer which
             failed prior therapies.

          6. Prior treatment with trastuzumab(≥2 cycles in the metastatic setting, or ≥3 months in
             adjuvant setting), and the patients are not available for the trastuzumab or lapatinib

          7. Previously reveived both Anthracyclin and Taxane.

          8. Required laboratory values including following parameters:

             ANC: ≥ 1.5 x 10^9/L; Platelet count: ≥ 90 x 10^9/L; Hemoglobin: ≥ 9.0 g/dL; Total
             bilirubin: ≤ 1.5 x upper limit of normal (ULN); ALT and AST: ≤ 2 x ULN(patients with
             liver metastases: </= 5 x ULN); BUN and Creatinine: ≤ 1.5 x ULN;LVEF: ≥ 50%;QTcF: <
             470 ms.

          9. Signed informed consent

        Exclusion Criteria:

          1. Received previous therapy with lapatinib, neratinib, pyrotinib or any other HER2
             directe tyrosine kinase inhibitor.

          2. Received previous therapy with capecitabine.

          3. History of receiving chemotherapy, target-therapy or investigational treatment within
             28 days prior to randomization. Received hormone therapy within 7 days prior to
             randomization.

          4. Brain metastases that are untreated, symptomatic, or require therapy to control
             symptoms.

          5. Current severe, uncontrolled systemic disease.

          6. Unable or unwilling to swallow tablets.
Clinical trial NCT02974907 (phase 3, status: completed)
Conditions: dry eye syndrome
ICD codes: H04.121, H04.122, H04.123, H04.129
Drugs: rgn-259, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Be at least 18 years of age;

          -  Provide written informed consent;

          -  Have a subject reported history of dry eye for at least 6 months

          -  Have a history of use or desire to use eye drops for dry eye symptoms within 6 months

        Exclusion Criteria:

          -  Have any clinically significant slit-lamp findings at Visit 1 that may include active
             blepharitis, meibomian gland dysfunction (MGD), lid margin inflammation or active
             ocular allergies that require therapeutic treatment, and/or in the opinion of the
             investigator may interfere with study parameters;

          -  Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active
             ocular inflammation at Visit 1;

          -  Have ab uncontrolled systemic disease:
Clinical trial NCT02978326 (phase 3, status: completed)
Conditions: postpartum depression
ICD codes: F53.0
Drugs: sage-217, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Subject either must have ceased lactating at screening or, if still lactating or
             actively breastfeeding at screening, must agree to temporarily cease giving breast
             milk to her infant(s)

          -  Subject has had a Major Depressive Episode that began no earlier than the third
             trimester and no later than the first 4 weeks following delivery, as diagnosed by the
             Structured Clinical Interview for DSM-5 Axis I Disorders (SCID-I)

          -  Subject is ≤ six months postpartum

        Key Exclusion Criteria:

          -  Active psychosis

          -  Attempted suicide associated with current episode of postpartum depression

          -  Medical history of seizures

          -  Medical history of bipolar disorder, schizophrenia, and/or schizoaffective disorder.

        Note: suicidal ideation is not an exclusion. Other protocol-defined inclusion/exclusion
        criteria may apply.
Clinical trial NCT02980874 (phase 3, status: terminated)
Conditions: macular edema, retinal vein occlusion
ICD codes: H59.033, H34.8130, H59.031, H59.032, H59.039, H34.8110, H34.8120, H34.8131, H34.8132, H34.8111, H34.8121, H34.8191, H34.8331, H34.8112
Drugs: suprachoroidal cls-ta, suprachoroidal sham, ivt aflibercept
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O
Reason stopped: 
    primary, 8-week efficacy endpoint not achieved. no additional benefit for subjects receiving a
    corticosteroid together with an intravitreal anti-vegf agent.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Has a clinical diagnosis of RVO in the study eye

          -  Has a CST of ≥ 300 µm in the study eye

          -  Has an ETDRS BCVA score of ≥ 20 letters read and ≤ 70 letters read in the study eye;

          -  Is naïve to local pharmacologic treatment for RVO in the study eye;

        Exclusion Criteria:

          -  Any active ocular disease or infection in the study eye other than RVO

          -  History of glaucoma, intraocular pressure > 21 mmHg or ocular hypertension requiring
             more than one medication

          -  Any uncontrolled systemic disease that, in the opinion of the Investigator, would
             preclude participation in the study

          -  Any evidence of neovascularization in the study eye